CN110505902B - 普利多匹定用于治疗脆性x综合征的应用 - Google Patents

普利多匹定用于治疗脆性x综合征的应用 Download PDF

Info

Publication number
CN110505902B
CN110505902B CN201880007913.2A CN201880007913A CN110505902B CN 110505902 B CN110505902 B CN 110505902B CN 201880007913 A CN201880007913 A CN 201880007913A CN 110505902 B CN110505902 B CN 110505902B
Authority
CN
China
Prior art keywords
pridopidine
subject
fxs
acid
vigabatrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880007913.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110505902A (zh
Inventor
迈克尔·海登
马哈茂德·阿卜杜勒侯赛因·普拉迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prenia Neurotherapy Co ltd
Agency for Science Technology and Research Singapore
National University of Singapore
Original Assignee
Prenia Neurotherapy Co ltd
Agency for Science Technology and Research Singapore
National University of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prenia Neurotherapy Co ltd, Agency for Science Technology and Research Singapore, National University of Singapore filed Critical Prenia Neurotherapy Co ltd
Publication of CN110505902A publication Critical patent/CN110505902A/zh
Application granted granted Critical
Publication of CN110505902B publication Critical patent/CN110505902B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
CN201880007913.2A 2017-01-20 2018-01-18 普利多匹定用于治疗脆性x综合征的应用 Active CN110505902B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448595P 2017-01-20 2017-01-20
US62/448,595 2017-01-20
PCT/US2018/014169 WO2018136600A1 (en) 2017-01-20 2018-01-18 Use of pridopidine for the treatment of fragile x syndrome

Publications (2)

Publication Number Publication Date
CN110505902A CN110505902A (zh) 2019-11-26
CN110505902B true CN110505902B (zh) 2022-11-11

Family

ID=62908348

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880007913.2A Active CN110505902B (zh) 2017-01-20 2018-01-18 普利多匹定用于治疗脆性x综合征的应用

Country Status (13)

Country Link
US (2) US11234973B2 (enExample)
EP (1) EP3570940B1 (enExample)
JP (1) JP7114604B2 (enExample)
CN (1) CN110505902B (enExample)
AU (1) AU2018210145B2 (enExample)
BR (1) BR112019015000A2 (enExample)
CA (1) CA3050700C (enExample)
DK (1) DK3570940T3 (enExample)
ES (1) ES2972205T3 (enExample)
HU (1) HUE068300T2 (enExample)
IL (1) IL268125B2 (enExample)
PL (1) PL3570940T3 (enExample)
WO (1) WO2018136600A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011298382A1 (en) 2010-09-03 2013-05-02 Teva Pharmaceuticals International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
MX2019002190A (es) 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
AU2018329628B2 (en) 2017-09-08 2021-04-22 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES
EP4088721B1 (en) * 2020-01-08 2025-09-17 Neuroventi Composition for treating fragile x syndrome or related developmental disorders, comprising lisuride compound as active ingredient
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
DK2146961T3 (da) 2007-04-12 2014-04-28 Ivax Int Gmbh N-oxid- og/eller di-N-oxidderivater af dopaminreceptorstabilisatorer/modulatorer udvisende forbedrede cardiovaskulære bivirkningsprofiler
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
CN103080343A (zh) 2010-07-02 2013-05-01 Skf公司 机械部件和用于表面硬化的方法
AU2011298382A1 (en) 2010-09-03 2013-05-02 Teva Pharmaceuticals International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
BR112013018898B1 (pt) * 2011-01-27 2021-10-05 Neuren Pharmaceuticals Limited Uso de ácido glicil-l-2-metilprolil-l-glutâmico e análogos do mesmo para o tratamento de transtornos do espectro do autismo
KR20140075703A (ko) 2011-09-07 2014-06-19 아이백스 인터내셔널 게엠베하 프리도피딘 하이드로클로라이드의 다형 형태
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 併用療法のための医薬組成物
HK1211483A1 (en) * 2012-09-27 2016-05-27 Teva Pharmaceutical Industries Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
KR102316933B1 (ko) 2013-06-21 2021-10-26 프리레니아 뉴로테라퓨틱스 엘티디. 헌팅턴병 치료를 위한 프리도피딘의 용도
DK3096759T3 (da) 2014-01-22 2022-05-09 Prilenia Neurotherapeutics Ltd Pridopidinformuleringer med modificeret frigivelse
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
JP2018505147A (ja) 2014-12-22 2018-02-22 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー プリドピジンのｌ−酒石酸塩
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease;Daniel Ryskamp等;《Neurobiol Dis》;20170105;第97卷;46-59 *

Also Published As

Publication number Publication date
WO2018136600A1 (en) 2018-07-26
HUE068300T2 (hu) 2024-12-28
IL268125A (en) 2019-09-26
US11234973B2 (en) 2022-02-01
CA3050700C (en) 2023-10-03
PL3570940T3 (pl) 2024-06-17
ES2972205T3 (es) 2024-06-11
BR112019015000A2 (pt) 2020-04-07
IL268125B2 (en) 2023-04-01
JP2020514313A (ja) 2020-05-21
IL268125B (en) 2022-12-01
US20190336488A1 (en) 2019-11-07
AU2018210145B2 (en) 2023-06-29
AU2018210145A1 (en) 2019-08-29
CN110505902A (zh) 2019-11-26
JP7114604B2 (ja) 2022-08-08
EP3570940A4 (en) 2020-10-28
DK3570940T3 (da) 2024-02-19
EP3570940A1 (en) 2019-11-27
CA3050700A1 (en) 2018-07-26
EP3570940B1 (en) 2023-12-13
US20220202798A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
CN110505902B (zh) 普利多匹定用于治疗脆性x综合征的应用
US11406625B2 (en) Method of treating amyotrophic lateral sclerosis with pridopidine
CN109952100A (zh) 普利多匹定用于治疗焦虑和抑郁的用途
Class et al. Patent application title: USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME Inventors: Michael Hayden (Herzliya, IL) Mahmoud Abdulhossein Pouladi (Singapore, SG) Assignees: PRILENIA NEUROTHERAPEUTICS LTD. NATIONAL UNIVERSITY OF SINGAPORE Agency For Science, Technology and Research
RU2374245C1 (ru) Лиганд с широким спектром одновременной рецепторной активности, фармацевтическая композиция, способ ее получения и лекарственное средство
van Dijk et al. Behavioural effects of trishomocubanes in rats with unilateral 6-hydroxydopamine lesions
HK40016661B (en) Pridopidine for use in the treatment of fragile x syndrome
HK40016661A (en) Pridopidine for use in the treatment of fragile x syndrome
BR122025001464A2 (pt) Uso de pridopidina e, opcionalmente, de um segundo composto para o tratamento de esclerose lateral amiotrófica (ela) e composição farmacêutica
CN114761008A (zh) 用于在患有痴呆的患者中治疗行为和心理症状的方法
HK40071167A (en) Methods for treating behavioral and psychological symptoms in patients with dementia
EA043430B1 (ru) Способ лечения бокового амиотрофического склероза придопидином
Manjunath Study of Effectiveness and Tolerability of Opipramol in the Treatment of Generalized Anxiety Disorder and Somatoform Disorders
TW202132278A (zh) 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant